BridgeMD
A Study to Investigate the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia
EU CTIS ID: 2024-518502-40-00
What this study is testing
Phase 1: To assess the safety profile and tolerability of pirtobrutinib in participants with ITP and select the doses for the Phase 2 part of this study Phase 2: To evaluate the efficacy of pirtobrutinib versus placebo in participants with ITP
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Are 18 years of age or older
- Have a confirmed diagnosis of primary ITP
- Have documented history of response to at least 1 previous treatment for ITP
- Have not responded to previous treatments for primary ITP
You likely can't join if
- Have a history of any blood clots or blockages in their blood vessels in the last 12 months
- Had a transfusion with blood or blood products or plasmapheresis within 14 days of the Phase 1 part of the study or within 28 days for the Phase 2 part of the study
- Have a history of significant cardiovascular disease
- Have a diagnosis or history of a blood-related cancer
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Republic of
- United States
- United Kingdom
- China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Republic of; United States; United Kingdom; China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.